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The Nonalcoholic Steatohepatitis Metabotype: Imbalance of
Circulating Amino Acids and Transamination Reactions Reflect
Impaired Mitochondrial Function
TO THE EDITOR:
We read with interest the article of Gaggini et al.
reporting plasma concentrations of amino acids (AAs)
in nonalcoholic fatty liver disease (NAFLD).(1) The
researchers observed that patients with NAFLD had
high levels of isoleucine and valine (branched-chain
amino acids; BCAA), tyrosine, alanine, lysine, and
glutamate. More specifically, the researchers found
that BCAA correlated with alanine aminotransferase
(ALT) and aspartate aminotransferase (AST) levels;
therefore, they concluded that plasma levels of amino-
transferases reflect increased transamination reactions,
and that amino acids are markers of hepatic inflamma-
tion and fibrosis. Although these results are confirma-
tory findings of knowledge that is already known and
of which the associated molecular mechanisms have
been extensively studied,(2) some points deserve to be
highlighted. For example, we observed that in patients
with NAFLD, circulating levels of some essential
AAs, L-glutamic acid, and other metabolites (2-
hydroxyglutarate), were significantly associated not
only with serum levels of AST, but also liver transcrip-
tional activity and protein level of aminotransferases(2)
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FIG. 1. Imbalance of circulating amino acids and transamination reactions in NAFLD. Figure depicts circulating metabolites up-
regulated in biopsy-proven NAFLD and the levels of which are significantly associated with liver expression of transaminases (ALT
and AST).(2) Upward pointing arrows highlight up-regulated levels of gluconeogenic amino acids (alanine, cysteine, methionine, aspar-
tate, arginine, and glutamic acid) and gluconeogenic or ketogenic amino acids (tyrosine and lysine, respectively).(2) Transamination
reactions: GPT (Alanine aminotransferase 1, enzyme entry: 2.6.1.2): L-Alanine 1 Oxoglutaric acid $ Pyruvic acid 1 L-Glutamic
acid. GPT2 (Alanine aminotransferase 2, enzyme entry: 2.6.1.2): L-Alanine 1 Oxoglutaric acid $ Pyruvic acid 1 L-Glutamic acid.
GOT1 (Aspartate aminotransferase, cytoplasmic, enzyme entry: 2.6.1.1 and 2.6.1.3): L-Aspartic acid 1 Oxoglutaric acid $ Oxalace-
tic acid 1 L-Glutamic acid. GOT2 (Aspartate aminotransferase, mitochondrial, enzyme entry: 2.6.1.1 and EC: 2.6.1.7): L-
Kynurenine 1 Oxoglutaric acid $ 4-(2-Aminophenyl)-2,4-dioxobutanoic acid 1 L-Glutamic acid. GOT1L1 (Putative aspartate ami-
notransferase, cytoplasmic 2, enzyme entry: 2.6.1.): L-Aspartic acid 1 Oxoglutaric acid $ Oxalacetic acid 1 L-Glutamic acid). *It
must be emphasized that in the skeletal muscle, especially under physiological conditions of starvation and pathological stress
responses, BCAA catabolism may be activated to support anaplerosis and acetyl-CoA as a substrate. It is controversial whether this
reaction is unique to the skeletal muscle and not other organs.
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(Fig. 1). We also found that 2-hydroxyglutaric acid, L-
glutamic acid, and alanine/pyruvate ratio were signifi-
cantly associated with NAFLD disease severity.(2)
Notably, L-alanine/pyruvate ratio significantly corre-
lated with body mass index even after adjusting for
homeostasis model assessment of insulin resistance.(2)
Furthermore, cross-sectional and longitudinal data
from the Framingham Heart Study showed implicated
dysregulated glutamate cycling and AA metabolism in
metabolic risk.(3) For instance, glutamic acid and 2-
ketoglutaric acid were both significantly associated
with ALT and AST in discovery (n 5 650) and repli-
cation (n 5 554) analysis.(3) Most important, among
119 plasma metabolites assessed, the top AA bio-
marker was glutamic acid, which was directly associ-
ated with obesity, dyslipidemia, and dysglycemia in
discovery and replication data sets.(3) The ratio serine/
glutamic acid, a reflection of serine-pyruvate and ala-
nine transaminase activity, was also significantly associ-
ated with metabolic syndrome components.
Interestingly, not only all above-mentioned meta-
bolic reactions occur in the mitochondrial matrix, but
each of the resulting metabolite is a by-product of the
Krebs cycle (Fig. 1).
Remarkably, transaminations of AAs, including
BCAA, are, in part, mediated by AST and ALT (Fig.
1). Likewise, NAFLD severity is associated with
impaired mitochondrial-(mt) function,(4,5) altered mt-
morphology,(4) and increased mt-genome variability.(5)
Together, it is plausible to speculate that the circulat-
ing “nonalcoholic steatohepatitis (NASH) metab-
otype” resembles a “mitochondrial disease.”
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REPLY:
We thank Sookoian et al. for the interesting com-
ments on our article.(1) However, it must be said they
have downplayed the novelty of our results that rely not
in the increase in BCAA, but rather in the importance
of other amino acids (AA), like glutamate (GLUT), ser-
ine (SER), glycine (GLY), and the new GSG index,
calculated as GLUT/(SER 1 GLY), that we found
able to well discriminate liver fibrosis F02 from F34.
We agree with them that the use of GLUT as a bio-
marker of altered liver metabolism has not been con-
sidered enough, although several studies have provided
evidences that GLUT is increased in metabolic dis-
eases (table 3, Gaggini et al.(1)). GLUT participates in
several metabolic reactions, from synthesis of glutathi-
one (GSH) and SER to transamination of alanine and
as substrate of the TCA cycle (Fig. 1). Increased ALT
has been used as a surrogate marker of nonalcoholic
fatty liver disease (NAFLD), although not all
NAFLDs have increased AST and ALT. This is not
surprising given that these are intracellular enzymes
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